Proteinase-activated receptor-2 (PAR2)

Vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2

John J. McGuire, Jiazhen Dai, Patricia Andrade-Gordon, Christopher Triggle, Morley D. Hollenberg

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We studied the actions of the proteinase-activated receptor-2- activating peptide (PAR2-AP) trans-cinnamoyl-LIGRLO-amide (tc- LI) in femoral (FA), renal, and small mesenteric (MA) arterial vessels from C57BL/6 [PAR2 (+/+)] and PAR2 (-/-) mice. The actions of tc-LI were compared with those of the parent PAR2-AP Ser-Leulle-Gly-Arg-Leu-amide (SLIGRL-amide; SLI-NH2). Either SLI-NH2 or tc-LI (0.1-10 μM) induced relaxation of either 9,11-dideoxy- 9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid (U46619)-or cirazoline-precontracted FA from PAR2 (+/+) in endotheliumintact preparations but did not relax vessels from PAR2 (-/-) mice. This FA relaxation by SLI-NH2 and by tc-LI was inhibited by 1) pretreatment with a combination of L-NG-nitroarginine methyl ester (L-NAME) and 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 2) precontraction with 30 mM KCl, or 3) removal of the endothelium. In contrast, tc-LI caused an L-NAME/ODQ/indomethacin-resistant relaxation of MA from PAR2 (+/+) mice. In contrast with SLI-NH2, tc-LI (>30 μM) contracted arteries from both PAR2 (-/-) and PAR2 (+/+) mice. Pretreatment of tissues with a combination of cyclopiazonic acid plus caffeine reduced significantly tc-LI-induced contractions, whereas nifedipine, CdCl2, and Ca2+-free conditions did not. Inhibitors of vascular muscarinic, α1-adrenergic, neurokinin, thromboxane A2, histamine, angiotensin II, or endothelin-1 receptors failed to inhibit contractions by 50 μM tc-LI. At resting tension, SLI-NH2 (>10 μM) contracted all arteries in an endothelium-independent manner but only from PAR2 (+/+) mice. We conclude that the endothelium- dependent vasodilation initiated by SLI-NH2 and tc-LI, but not the endothelium-independent contraction initiated by tc-LI, are due to the activation of PAR2. Indeed, the data from PAR2 (-/-) mice indicate that tc-LI, in addition to activating PAR2, is an agonist of vascular smooth muscle contraction via a receptor different than PAR2.

Original languageEnglish
Pages (from-to)985-992
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume303
Issue number3
DOIs
Publication statusPublished - 1 Dec 2002
Externally publishedYes

Fingerprint

PAR-2 Receptor
Blood Vessels
Peptides
Endothelium
Thigh
NG-Nitroarginine Methyl Ester
seryl-leucyl-isoleucyl-glycyl-arginyl-leucine
Amides
Arteries
Endothelin A Receptors
Cadmium Chloride
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Thromboxane A2
Nifedipine
Muscle Contraction
Caffeine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Proteinase-activated receptor-2 (PAR2) : Vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. / McGuire, John J.; Dai, Jiazhen; Andrade-Gordon, Patricia; Triggle, Christopher; Hollenberg, Morley D.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 303, No. 3, 01.12.2002, p. 985-992.

Research output: Contribution to journalArticle

@article{30206c2f370e47c8a8b1458cc549326e,
title = "Proteinase-activated receptor-2 (PAR2): Vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2",
abstract = "We studied the actions of the proteinase-activated receptor-2- activating peptide (PAR2-AP) trans-cinnamoyl-LIGRLO-amide (tc- LI) in femoral (FA), renal, and small mesenteric (MA) arterial vessels from C57BL/6 [PAR2 (+/+)] and PAR2 (-/-) mice. The actions of tc-LI were compared with those of the parent PAR2-AP Ser-Leulle-Gly-Arg-Leu-amide (SLIGRL-amide; SLI-NH2). Either SLI-NH2 or tc-LI (0.1-10 μM) induced relaxation of either 9,11-dideoxy- 9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid (U46619)-or cirazoline-precontracted FA from PAR2 (+/+) in endotheliumintact preparations but did not relax vessels from PAR2 (-/-) mice. This FA relaxation by SLI-NH2 and by tc-LI was inhibited by 1) pretreatment with a combination of L-NG-nitroarginine methyl ester (L-NAME) and 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 2) precontraction with 30 mM KCl, or 3) removal of the endothelium. In contrast, tc-LI caused an L-NAME/ODQ/indomethacin-resistant relaxation of MA from PAR2 (+/+) mice. In contrast with SLI-NH2, tc-LI (>30 μM) contracted arteries from both PAR2 (-/-) and PAR2 (+/+) mice. Pretreatment of tissues with a combination of cyclopiazonic acid plus caffeine reduced significantly tc-LI-induced contractions, whereas nifedipine, CdCl2, and Ca2+-free conditions did not. Inhibitors of vascular muscarinic, α1-adrenergic, neurokinin, thromboxane A2, histamine, angiotensin II, or endothelin-1 receptors failed to inhibit contractions by 50 μM tc-LI. At resting tension, SLI-NH2 (>10 μM) contracted all arteries in an endothelium-independent manner but only from PAR2 (+/+) mice. We conclude that the endothelium- dependent vasodilation initiated by SLI-NH2 and tc-LI, but not the endothelium-independent contraction initiated by tc-LI, are due to the activation of PAR2. Indeed, the data from PAR2 (-/-) mice indicate that tc-LI, in addition to activating PAR2, is an agonist of vascular smooth muscle contraction via a receptor different than PAR2.",
author = "McGuire, {John J.} and Jiazhen Dai and Patricia Andrade-Gordon and Christopher Triggle and Hollenberg, {Morley D.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1124/jpet.102.040352",
language = "English",
volume = "303",
pages = "985--992",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Proteinase-activated receptor-2 (PAR2)

T2 - Vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2

AU - McGuire, John J.

AU - Dai, Jiazhen

AU - Andrade-Gordon, Patricia

AU - Triggle, Christopher

AU - Hollenberg, Morley D.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - We studied the actions of the proteinase-activated receptor-2- activating peptide (PAR2-AP) trans-cinnamoyl-LIGRLO-amide (tc- LI) in femoral (FA), renal, and small mesenteric (MA) arterial vessels from C57BL/6 [PAR2 (+/+)] and PAR2 (-/-) mice. The actions of tc-LI were compared with those of the parent PAR2-AP Ser-Leulle-Gly-Arg-Leu-amide (SLIGRL-amide; SLI-NH2). Either SLI-NH2 or tc-LI (0.1-10 μM) induced relaxation of either 9,11-dideoxy- 9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid (U46619)-or cirazoline-precontracted FA from PAR2 (+/+) in endotheliumintact preparations but did not relax vessels from PAR2 (-/-) mice. This FA relaxation by SLI-NH2 and by tc-LI was inhibited by 1) pretreatment with a combination of L-NG-nitroarginine methyl ester (L-NAME) and 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 2) precontraction with 30 mM KCl, or 3) removal of the endothelium. In contrast, tc-LI caused an L-NAME/ODQ/indomethacin-resistant relaxation of MA from PAR2 (+/+) mice. In contrast with SLI-NH2, tc-LI (>30 μM) contracted arteries from both PAR2 (-/-) and PAR2 (+/+) mice. Pretreatment of tissues with a combination of cyclopiazonic acid plus caffeine reduced significantly tc-LI-induced contractions, whereas nifedipine, CdCl2, and Ca2+-free conditions did not. Inhibitors of vascular muscarinic, α1-adrenergic, neurokinin, thromboxane A2, histamine, angiotensin II, or endothelin-1 receptors failed to inhibit contractions by 50 μM tc-LI. At resting tension, SLI-NH2 (>10 μM) contracted all arteries in an endothelium-independent manner but only from PAR2 (+/+) mice. We conclude that the endothelium- dependent vasodilation initiated by SLI-NH2 and tc-LI, but not the endothelium-independent contraction initiated by tc-LI, are due to the activation of PAR2. Indeed, the data from PAR2 (-/-) mice indicate that tc-LI, in addition to activating PAR2, is an agonist of vascular smooth muscle contraction via a receptor different than PAR2.

AB - We studied the actions of the proteinase-activated receptor-2- activating peptide (PAR2-AP) trans-cinnamoyl-LIGRLO-amide (tc- LI) in femoral (FA), renal, and small mesenteric (MA) arterial vessels from C57BL/6 [PAR2 (+/+)] and PAR2 (-/-) mice. The actions of tc-LI were compared with those of the parent PAR2-AP Ser-Leulle-Gly-Arg-Leu-amide (SLIGRL-amide; SLI-NH2). Either SLI-NH2 or tc-LI (0.1-10 μM) induced relaxation of either 9,11-dideoxy- 9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid (U46619)-or cirazoline-precontracted FA from PAR2 (+/+) in endotheliumintact preparations but did not relax vessels from PAR2 (-/-) mice. This FA relaxation by SLI-NH2 and by tc-LI was inhibited by 1) pretreatment with a combination of L-NG-nitroarginine methyl ester (L-NAME) and 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 2) precontraction with 30 mM KCl, or 3) removal of the endothelium. In contrast, tc-LI caused an L-NAME/ODQ/indomethacin-resistant relaxation of MA from PAR2 (+/+) mice. In contrast with SLI-NH2, tc-LI (>30 μM) contracted arteries from both PAR2 (-/-) and PAR2 (+/+) mice. Pretreatment of tissues with a combination of cyclopiazonic acid plus caffeine reduced significantly tc-LI-induced contractions, whereas nifedipine, CdCl2, and Ca2+-free conditions did not. Inhibitors of vascular muscarinic, α1-adrenergic, neurokinin, thromboxane A2, histamine, angiotensin II, or endothelin-1 receptors failed to inhibit contractions by 50 μM tc-LI. At resting tension, SLI-NH2 (>10 μM) contracted all arteries in an endothelium-independent manner but only from PAR2 (+/+) mice. We conclude that the endothelium- dependent vasodilation initiated by SLI-NH2 and tc-LI, but not the endothelium-independent contraction initiated by tc-LI, are due to the activation of PAR2. Indeed, the data from PAR2 (-/-) mice indicate that tc-LI, in addition to activating PAR2, is an agonist of vascular smooth muscle contraction via a receptor different than PAR2.

UR - http://www.scopus.com/inward/record.url?scp=0036895877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036895877&partnerID=8YFLogxK

U2 - 10.1124/jpet.102.040352

DO - 10.1124/jpet.102.040352

M3 - Article

VL - 303

SP - 985

EP - 992

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -